Latest ArticlesTo investigate and analyze the adverse event (AE) signals associated with trastuzumab deruxtecan, and provide scientific basic for clinical use and regulatory decision-making.
AE reports related to trastuzumab deruxtecan from its market launch to Nov 24, 2024, were retrieved from the WHO-VigiAccess and FAERS databases. Disproportionality analysis methods, including reporting odds ratio, proportional reporting ratio, and Bayesian confidence propagation neural network, were used for signal detection.
A total of 12 545 reports from WHO-VigiAccess and 5 924 reports from the FAERS database related to trastuzumab deruxtecan were included. A total of 243 significant AE signals were identified, involving 20 system organ classification, with a focus on general disorders and administration site reactions, gastrointestinal disorders, respiratory, thoracic and mediastinal disorders, and blood and lymphatic system disorders. Additionally, 114 new potential risk signals were detected (accounting for 46.91%), including weight gain, ascites, pleural effusion, sepsis, pulmonary embolism, and PJP.
Continuous monitoring of drug safety is essential during trastuzumab deruxtecan therapy to maximize therapeutic outcomes and minimize risks.
Transfer RNA-derived small RNA (tsRNA) is a tRNA fragment produced by cutting precursors or mature tRNA through endonucleases. It has functions such as regulating gene expression, epigenetics and immune responses. It has been confirmed to play a role in multiple system diseases and their tumors, and is closely related to kidney diseases.This paper reviewed the generation and classification of tsRNA, its biological functions, and its role in kidney diseases, and elaborated on the significance of tsRNA as an early diagnostic marker and therapeutic target for kidney diseases, aiming to provide a reference for clinical practice.
In 2022, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association jointly released a clinical practice guideline that introduced the term progressive pulmonary fibrosis (PPF) to collectively refer to the progressive fibrotic phenotypes of interstitial lung diseases other than idiopathic pulmonary fibrosis (IPF). These diseases may exhibit clinical course characteristics and core mechanisms of fibrosis similar to those of IPF, even after standardized treatment. Currently, the two anti-fibrotic drugs nintedanib and pirfenidone approved by the U.S. Food and Drug Administration, can only slow the decline in lung function in patients with IPF, but cannot reverse fibrosis. Due to the significant heterogeneity of PPF patient population and complex enrollment criteria, clinical trials targeting PPF often terminate due to recruitment challenges. Consequently, current drug development strategies primarily select IPF as the initial indication and then gradually expand to other fibrotic lung diseases after confirming effectiveness. In the research and development pipeline, most candidate drugs remain in the early stages of clinical development, with only a few advancing to phase Ⅱ/Ⅲ clinical studies and simultaneously exploring the PPF indication. Notably, in 2024, the world's first anti-fibrotic drug designed entirely using artificial intelligence (AI), INS018-055, successfully progressed to Phase Ⅱ clinical trials, marking a significant breakthrough application of AI technology in drug development. This article systematically dissected the conceptual framework of PPF, covering its definition, disease spectrum, epidemiological characteristics, and molecular mechanisms, while reviewed the latest clinical research advancements from the perspective of anti-fibrotic treatment, aiming to provide a theoretical foundation for the discovery of new targets and translational research.
Mild cognitive impairment 、 (MCI) is a common neurodegenerative disease that is characterized by memory impairment or progressive decline in other cognitive domains. The incidence of MCI among people aged 65 and above is 7.7% to 28.3%, and 10% to 15% of these patients will progress to dementia. Early intervention for MCI can alleviate the impact of cognitive dysfunction on quality of life as well as reduce the prevalence of dementia in patients.Currently, the treatment methods for MCI in western medicine are limited and poor effective. In recent years, the safety and efficacy of using traditional Chinese medicine (TCM) to treat MCI under the guidance of TCM theories have been effectively verified in clinical practice. Meanwhile, modern science and technology have also revealed the possible mechanism of TCM prevention and treatment of MCI from the aspects of inhibiting β-amyloid deposition, Tau protein hyperphosphorylation, inflammatory response, oxidative stress and regulating cholinergic system. This article reviewed the clinical application and mechanism research progress of TCM in treating MCI.
Vascular endothelial cell dysfunction is a core component of various chronic diseases and is closely related to the health status of the body. This article systematically explored the translational research on vascular endothelial cells from the perspectives of regenerative medicine, preventive medicine, and preventing or reversing vascular aging. It aimed to integrate multidisciplinary perspectives on vascular research, deepen the understanding of the central role of vascular endothelium cells in maintaining organ function, systemic health, and promoting healthy aging, and provide new ideas for the prevention and treatment of related diseases.
Vascular endothelial cells play a crucial role in the body. Due to their large surface area and the fact that body cells are generally located within the oxygen diffusion limit of capillaries(100-150 μm), the microvascular network constitutes a key interface between the circulatory system and the parenchyma of organs. Traditionally, endothelial cells have mainly been regarded as functional actors that respond to external stimuli(such as inflammatory factors). Recent research has revised this passive perspective. Currently, endothelial cells have been redefined as active "gatekeepers"due to their strategic position between circulation and tissue. They precisely regulate the local environment by secreting various paracrine signaling molecules. This article briefly summarized the response and conduction functions of vascular endothelial cells in the vascular wall, and discussed their key roles in physiological and pathological processes.
The vascular endothelium differentiates organically in both structure and molecules, enabling it to execute specific functions that are tailored to the microenvironment. Continuous endothelial cells with firmly sealing tight junctions are found in tissue, in which the endothelial cells form a barrier, such as in the brain, lung, or muscle.Discontinuous endothelium are present in organs with filtration function(e.g., kidney) or that release substances into the bloodstream(endocrine glands). Sinusoidal endothelium forms a discontinuous layer with intracellular and intercellular sieve-like gaps. They are found in immune active organs such as the bones, spleen, and liver. This article reviewed the analysis and utilization of mechanism of vascular heterogeneity, aiming to provide references for the development of new therapeutic targets for related diseases.
To explore the molecular mechanism of Tongqiao Huoxue decoction in regulating microglia for Alzheimer's disease(AD).
The AD cell model was established by stimulating BV2 cells with lipopolysaccharide(LPS), and the effect of Tongqiao Huoxue decoction was evaluated through the following experiments:①Cell viability and apoptosis rate were detected by CCK-8 method and flow cytometry. ② Inflammatory factors(IL-6, TNF-α and IL-1β) and oxidative stress indicators(ROS, MDA, SOD) were determined by ELISA. ③Western blot was used to detect the expression of NLRP3 inflammasome. ④Mitochondrial functions(ATP production, membrane potential, and superoxide generation) were determined using commercial kits.
Tongqiao Huoxue decoction significantly inhibited the increase in BV2 cell viability induced by LPS(t=5.289—14.406, P<0.05) and the decrease in apoptosis rate(t=14.518, P<0.05), and down-regulated the expression of inflammatory factors, reversed oxidative stress(up-regulated ROS and MDA, down-regulated SOD), with statistically significant differences(P<0.05). Tongqiao Huoxue decoction can improve mitochondrial dysfunction caused by LPS: restore ATP production, stabilize membrane potential, and reduce superoxide generation(P<0.05). Mechanism studies have shown that Tongqiao Huoxue decoction exerts a protective effect by down-regulating the expression of NLRP3 inflammasome, and overexpression of NLRP3 can reverse this effect(P<0.05).
Tongqiao Huoxue decoction exerts neuroprotective effects by inhibiting the activation of NLRP3 inflammasome, improving the inflammatory response and oxidative stress state of microglia, and correcting mitochondrial dysfunction.
To explore the clinical application value of oral electrolyte solution after surgery in patients undergoing endoscopic resection of colorectal polyps, and to evaluate the impact on postoperative intestinal function recovery, patient comfort and the incidence of adverse reactions.
A total of 140 patients who underwent endoscopic resection of colorectal polyps at the Tenth People's Hospital from March 2024 to June 2024 were selected and divided into the experimental group and the control group, with 70 cases in each group. Patients in the experimental group took 400 mL of electrolyte formula food orally 2 hours after the operation. The control group was given sterile water of the same volume. The first postoperative exhaust, defecation and hospital stay, the visual analogue scale, self-rating anxiety scale, self-rating depression scale, and adverse reactions were compared between the two groups.
The first postoperative exhaust, defecation and hospital stay in the experimental group were all shorter than those in the control group(P<0.001). The postoperative levels of blood potassium and blood glucose in the control group were significantly lower than those in the experimental group(P<0.05). The scores of the postoperative analogue scale, self-rating anxiety scale and self-rating depression scale in the experimental group were better than those in the control group, and the differences were statistically significant(P<0.001). The incidence of adverse reactions was 2.86% in the experimental group and 14.29% in the control group, and the difference was statistically significant(P<0.001).
Oral administration of electrolyte solution after surgery can accelerate the recovery of intestinal function, improve the postoperative comfort of patients, and alleviate the adverse reactions of patients. It can provide a new management approach for the rapid recovery of patients after colorectal polyp resection.